Long-term treatment in rheumatoid arthritis: do biological and targeted-synthetic DMARDs increase the risk of malignancy?

被引：1
|
作者：
Fagni, Filippo [1 ,2 ]
Simon, David [1 ,2 ,3 ]
机构：
[1] Friedrich Alexander Univ FAU Erlangen Nurnberg, Dept Internal Med Rheumatol & Immunol 3, Ulmenweg 18, D-91054 Erlangen, Germany
[2] Friedrich Alexander Univ FAU Erlangen Nurnberg, Deutsch Zentrum Immuntherapie, Erlangen, Germany
[3] Univ Klinikum Erlangen, Ulmenweg 18, D-91054 Erlangen, Germany
来源：
RHEUMATOLOGY | 2022年 / 61卷 / 05期
关键词：
INHIBITOR; RITUXIMAB;
D O I：
10.1093/rheumatology/keab750
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1758 / 1759
页数：2
相关论文
共 50 条
  • [1] Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?
    Ozsoy, Zehra
    Ozdemir, Adem
    Ekici, Mustafa
    Bilgin, Emre
    Kilic, Levent
    Kiraz, Sedat
    Saribas, Zeynep
    Sener, Burcin
    Karadag, Omer
    RHEUMATOLOGY INTERNATIONAL, 2023, 43 (08) : 1445 - 1451
  • [2] Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?
    Zehra Ozsoy
    Adem Ozdemir
    Mustafa Ekici
    Emre Bilgin
    Levent Kılıc
    Sedat Kiraz
    Zeynep Sarıbas
    Burçin Sener
    Omer Karadag
    Rheumatology International, 2023, 43 : 1445 - 1451
  • [3] Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis
    Orsolini, Giovanni
    Fassio, Angelo
    Rossini, Maurizio
    Adami, Giovanni
    Giollo, Alessandro
    Caimmi, Cristian
    Idolazzi, Luca
    Viapiana, Ombretta
    Gatti, Davide
    PHARMACOLOGICAL RESEARCH, 2019, 147
  • [4] PREDICTION OF TREATMENT DISCONTINUATION DUE TO ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS USED BIOLOGICAL DMARDS AND TARGETED SYNTHETIC DMARDS
    Koltsova, E.
    Lukina, G.
    Shmidt, E.
    Lytkina, K.
    Zhilyaev, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1211 - 1211
  • [5] PERIODONTAL DISEASE IN RHEUMATOID ARTHRITIS: RESULTS FROM A COHORT AT TREATMENT WITH BIOLOGICAL, CLASSICAL AND TARGETED SYNTHETIC DMARDS
    Dos-Santos, R.
    Otero, F.
    Perez-Pampin, E.
    Mera Varela, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 524 - 524
  • [6] Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
    Jung, Ju-Yang
    Lee, Eunyoung
    Kim, Ji-Won
    Suh, Chang-Hee
    Shin, Kichul
    Kim, Jinhyun
    Kim, Hyoun-Ah
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [7] Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
    Ju-Yang Jung
    Eunyoung Lee
    Ji-Won Kim
    Chang-Hee Suh
    Kichul Shin
    Jinhyun Kim
    Hyoun-Ah Kim
    Arthritis Research & Therapy, 25
  • [8] Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review
    Gialouri, Chrysoula G.
    Pappa, Maria
    Evangelatos, Gerasimos
    Nikiphorou, Elena
    Fragoulis, George E.
    AUTOIMMUNITY REVIEWS, 2023, 22 (07)
  • [9] Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study
    Sonomoto, Koshiro
    Nakayamada, Shingo
    Fujino, Yoshihisa
    Miyata, Hiroko
    Kubo, Satoshi
    Fujita, Yuya
    Inoue, Yoshino
    Matsunaga, Satsuki
    Iwata, Shigeru
    Hanami, Kentaro
    Todoroki, Yasuyuki
    Yoshinari-Korekoda, Hiroko
    Kawabe, Akio
    Yamaguchi, Ayako
    Ueno, Masanobu
    Satoh-Kanda, Yurie
    Kanda, Ryuichiro
    Funada, Masashi
    Ohkubo, Naoaki
    Kusaka, Katsuhide
    Kosaka, Shumpei
    Nagayasu, Atsushi
    Fukuyo, Shunsuke
    Nawata, Masao
    Miyazaki, Yusuke
    Tokunaga, Mikiko
    Tanaka, Kenichi
    Okada, Yosuke
    Tanaka, Yoshiya
    RHEUMATOLOGY, 2023, 63 (08) : 2239 - 2248
  • [10] FRAILTY AND RISK OF ADVERSE OUTCOMES IN BIOLOGIC OR TARGETED-SYNTHETIC DMARD TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
    Singh, N.
    Gold, L.
    Wysham, K.
    Andrews, J.
    O'hare, A.
    Makris, U.
    Lee, J.
    George, M.
    England, B.
    Baker, J.
    Jarvik, J.
    Heagerty, P.
    Singh, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 600 - 600
12345